Skip to main content
Figure 4 | Journal of Nanobiotechnology

Figure 4

From: A nanocomplex that is both tumor cell-selective and cancer gene-specific for anaplastic large cell lymphoma

Figure 4

Optimization of the specific cell binding and carrying capacity of the nanocomplexes. A, Synthetic Cy5-conjugated ssDNA reporter molecules were incorporated into the PEI-citrate nanocores at different ratios (moles of nitrogen in PEI to moles of phosphate in ssDNA) as indicated. Reduction of the PEI-medicated non-specific cell binding was then monitored by flow cytometry. B, To gain specific cell binding capacity, the CD30 aptamer was incorporated into PEI-citrate nanocores along with the Cy5-ssDNA reporter to form a test nanocomplex. Different ratios of PEI-citrate nanocores to total oligonucleotides (moles of nitrogen in PEI/total moles of phosphate from both the aptamer and ssDNA) were tested as indicated, while the aptamer and Cy5-ssDNA were used at a fixed ratio of 1:1 (mol/mol). The CD30 aptamer-mediated specific binding to Karpas 299 cells was confirmed using flow cytometry. C, To optimize the maximal carrying capacity, the nanocomplex was formulated using a fixed ratio of PEI-citrate nanocores to total oligonucleotides (1:1 ratio as showed in B), but the ratios of the CD30 aptamer and Cy5-ssDNA reporter were altered as indicated (mol/mol). The carrying capacity of Cy5-ssDNA reporter by the nanocomplex with specific binding to Karpas 299 cells was quantified using flow cytometry.

Back to article page